Effects of Probiotics on Inflammatory Bowel Diseases: A Bibliometric Analysis

Çıracı, Enver; Ertal Akgöz, Ezgi; Elgün, Tuğba; Çelik, Fatma

year 19, Issue 5 (September - October 2025) Iran J Med Microbiol 2025, 19(5): 291-301 | Back to browse issues page

Mendeley

Zotero

RefWorks

Çıracı E, Ertal Akgöz E, Elgün T, Çelik F. Effects of Probiotics on Inflammatory Bowel Diseases: A Bibliometric Analysis. Iran J Med Microbiol 2025; 19 (5) :291-301
URL: http://ijmm.ir/article-1-2596-en.html

Effects of Probiotics on Inflammatory Bowel Diseases: A Bibliometric Analysis

Enver Çıracı¹

, Ezgi Ertal Akgöz²

, Tuğba Elgün³

, Fatma Çelik⁴

1- Department of Biochemistry, Faculty of Pharmacy, Biruni University, Istanbul, Türkiye
2- Department of Nutrition and Dietetics, Faculty of Health Sciences, Biruni University, Istanbul, Türkiye , eertal@biruni.edu.tr
3- Department of Medical Biology, Faculty of Medicine, Biruni University, Istanbul, Türkiye
4- Department of Nutrition and Dietetics, Faculty of Health Sciences, Biruni University, Istanbul, Türkiye

Abstract: (482 Views)

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease Loss of tolerance to intestinal microorganisms and abnormal intestinal immunity that lead to intestinal mucosa inflammation are its characteristics. This study aimed to evaluate the global research trends (2014–2023) on the effect of probiotics on IBD, focusing on publication patterns, subject areas, involved countries, and citations. In this study, Web of Science Core Collection and Scopus databases and VOSviewer software were used for bibliometric analysis. Studies covering the years 2014-2023 and keywords ‘microbiome’ OR ‘microbiota’ OR ‘gut microbiota’ OR ‘intestinal microbiome’ OR ‘dysbiosis’ OR ‘probiotics’ AND ‘IBD’ OR ‘Inflammatory Bowel Disease’ OR ‘Ulcerative colitis’ OR ‘Enterocolitis’ OR ‘Crohn's Disease’ in the title were included. Based on the analysis, the current situation on this topic has been determined. A total of 255,236 and 12,286 scientific documents were identified in the Web of Science and the Scopus, respectively between 2014-2023 years worldwide. Gastroenterology and Hepatology followed by Microbiology are the disciplines with the most studies in this field. The most frequently used keywords include “Probiotics”, “Inflammatory Bowel Disease”, “Gut Microbiota”, and “Ulcerative Colitis”. Recent studies address topics such as epigenetics, metabolites, and fecal microbiota transplantation. This study shows that further research into the links between the microbiota and inflammatory bowel diseases could improve the clinical application and treatment strategies of probiotics. Future research focusing on epigenetic and molecular regulatory mechanisms could contribute to the development of new approaches in this field.

Keywords: Bibliometrics, Gastrointestinal Microbiome, Inflammatory Bowel Disease, Microbiota, Probiotics

Full-Text [PDF 1025 kb] (37 Downloads)

Type of Study: Systematic Review | Subject: Scientometric Analysis
Received: 2025/07/17 | Accepted: 2025/10/10 | ePublished: 2025/11/11

References

1. Berg D, Clemente JC, Colombel JF. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?. Expert Rev Gastroenterol Hepatol. 2015;9(6):781-95. [DOI:10.1586/17474124.2015.1013031] [PMID]

2. Wright EK, Kamm MA, Teo SM, Inouye M, Wagner J, Kirkwood CD. Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review. Inflammatory Bowel Dis. 2015;21(6):1219-28. [DOI:10.1097/MIB.0000000000000382] [PMID] [PMCID]

3. Shen N, Clemente JC. Engineering the microbiome: a novel approach to immunotherapy for allergic and immune diseases. Curr Allergy Asthma Rep. 2015;15:1-10. [DOI:10.1007/s11882-015-0538-9] [PMID]

4. Haag LM, Siegmund B. Intestinal microbiota and the innate immune system-a crosstalk in Crohn's disease pathogenesis. Front Immunol. 2015;6:489. [DOI:10.3389/fimmu.2015.00489]

5. Lane ER, Zisman TL, Suskind DL. The microbiota in inflammatory bowel disease: current and therapeutic insights. J Inflamm Res. 2017;10:63-73. [DOI:10.2147/JIR.S116088] [PMID] [PMCID]

6. Chu H. Host gene-microbiome interactions: molecular mechanisms in inflammatory bowel disease. Genome Med. 2017;9(1):69. [DOI:10.1186/s13073-017-0459-4] [PMID] [PMCID]

7. Kang S, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflammatory Bowel Dis. 2010;16(12):2034-42. [DOI:10.1002/ibd.21319] [PMID]

8. Estevinho MM, Yuan Y, Rodríguez-Lago I, Sousa-Pimenta M, Dias CC, Barreiro-de Acosta M, et al. Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials. United Eur Gastroenterol J. 2024;12(7):960-81. [DOI:10.1002/ueg2.12636] [PMID] [PMCID]

9. Xu M, Zhang W, Lin B, Lei Y, Zhang Y, Zhang Y, et al. Efficacy of probiotic supplementation and impact on fecal microbiota in patients with inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2025;83(2):e65-e73. [DOI:10.1093/nutrit/nuae022] [PMID]

10. Zhang XF, Guan XX, Tang YJ, Sun JF, Wang XK, Wang WD, et al. Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis. Eur J Nutr. 2021;60(5):2855-75. [DOI:10.1007/s00394-021-02503-5] [PMID]

11. Öztürk O, Kocaman R, Kanbach DK. How to design bibliometric research: an overview and a framework proposal. Rev Manag Sci. 2024;18(11):3333-61. [DOI:10.1007/s11846-024-00738-0]

12. Frontiers Media SA. History of Frontiers. Lausanne: Frontiers Media SA; [cited 2025 Oct 20]. Available from: [https://www.frontiersin.org/about/history]

13. MDPI. History of Nutrients. Basel: MDPI; [cited 2025 Oct 20]. Available from: [https://www.mdpi.com/journal/nutrients/history]

14. Oxford University Press. Inflammatory Bowel Diseases - Volume 1, Issue 1. New York: Oxford University Press; [cited 2025 Oct 20]. Available from: [https://academic.oup.com/ibdjournal/issue/1/1]

15. MDPI. History of International Journal of Molecular Sciences [Internet]. Basel: MDPI; [cited 2025 Oct 20]. Available from: [https://www.mdpi.com/journal/ijms/history]

16. Clarivate Analytics. Institutions leading IBD and probiotics research: Bibliometric analysis. Web of Science; [cited 2024 March 07]. Available from: [https://www.webofscience.com/wos/woscc/summary/303c5908-7a5a-4877-bbdd-4b9c4bd99287-d2722d80/relevan]

17. Frank DN, Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci. 2007;104(34):13780-5. [DOI:10.1073/pnas.0706625104] [PMID] [PMCID]

18. Hansen R, Russell RK, Reiff C, Louis P, McIntosh F, Berry S, et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. The Am J Gastroenterol. 2012;107(12):1913-22. [DOI:10.1038/ajg.2012.335] [PMID]

19. Swidsinski A, Dörffel Y, Loening-Baucke V, Gille C, Göktas Ö, Reißhauer A, et al. Reduced mass and diversity of the colonic microbiome in patients with multiple sclerosis and their improvement with ketogenic diet. Front Microbiol. 2017;8:1141. [DOI:10.3389/fmicb.2017.01141] [PMID] [PMCID]

20. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102-9. [DOI:10.1053/j.gastro.2015.04.001] [PMID]

21. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11(5):853-8. [DOI:10.1046/j.1365-2036.1997.00225.x] [PMID]

22. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731-6. [DOI:10.1073/pnas.0804812105] [PMID] [PMCID]

23. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Treuren WV, Ren B, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host & Microbe. 2014;15(3):382-92. [DOI:10.1016/j.chom.2014.02.005] [PMID] [PMCID]

24. Morgan XC, Kabakchiev B, Waldron L, Tyler AD, Tickle TL, Milgrom R, et al. Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease. Genome Biol. 2015;16(1):67. [DOI:10.1186/s13059-015-0637-x] [PMID] [PMCID]

25. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152(2):327-39. [DOI:10.1053/j.gastro.2016.10.012] [PMID] [PMCID]

26. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations. J Crohn's Colitis. 2017;11(2):135-49. [DOI:10.1093/ecco-jcc/jjw169] [PMID]

27. Guslandi M. Role of probiotics in Crohn's disease and in pouchitis. J Clin Gastroenterol. 2015;49:S46-9. [DOI:10.1097/MCG.0000000000000351] [PMID]

28. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51(3):405-9. [DOI:10.1136/gut.51.3.405] [PMID] [PMCID]

29. Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, et al. Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. 2019;8(3):126. [DOI:10.3390/pathogens8030126] [PMID] [PMCID]

30. Zuo T, Ng SC. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front Microbiol. 2018;9:2247. [DOI:10.3389/fmicb.2018.02247] [PMID] [PMCID]

31. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1-10. [DOI:10.1007/s12328-017-0813-5] [PMID]

32. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. InSeminars in immunopathology. 2015 Jan (Vol. 37, No. 1, pp. 47-55). Berlin, Heidelberg, Germany: Springer. [DOI:10.1007/s00281-014-0454-4] [PMID] [PMCID]

33. Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?. World J Gastroenterol. 2014;20(5):1192. [DOI:10.3748/wjg.v20.i5.1192] [PMID] [PMCID]

34. Eom T, Kim YS, Choi CH, Sadowsky MJ, Unno T. Current understanding of microbiota-and dietary-therapies for treating inflammatory bowel disease. J Microbiol. 2018;56(3):189-98. [DOI:10.1007/s12275-018-8049-8] [PMID]

35. Abraham BP, Quigley EM. Probiotics in inflammatory bowel disease. Gastroenterol Clin. 2017;46(4):769-82. [DOI:10.1016/j.gtc.2017.08.003] [PMID]

36. Wasilewski A, Zielińska M, Storr M, Fichna J. Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease. Inflammatory Bowel Dis. 2015;21(7):1674-82. [DOI:10.1097/MIB.0000000000000364] [PMID]

37. Hu Y, Chen Z, Xu C, Kan S, Chen D. Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel disease. Nutrients. 2022;14(23):5140. [DOI:10.3390/nu14235140] [PMID] [PMCID]

38. Li J, Butcher J, Mack D, Stintzi A. Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease. Inflammatory Bowel Dis. 2015;21(1):139-53. [DOI:10.1097/MIB.0000000000000215] [PMID]

39. Bjarnason I, Sission G. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology. 2019;27(3):465. [DOI:10.1007/s10787-019-00595-4] [PMID] [PMCID]

40. Xu P, Lv T, Dong S, Cui Z, Luo X, Jia B, et al. Association between intestinal microbiome and inflammatory bowel disease: Insights from bibliometric analysis. Comput Struct Biotechnol J. 2022;20:1716-25. [DOI:10.1016/j.csbj.2022.04.006] [PMID] [PMCID]

41. Zhang T, Zhang B, Tian W, Wang F, Zhang J, Ma X, et al. Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021. Frontiers in Pharmacology. 2022;13:951004. [DOI:10.3389/fphar.2022.951004] [PMID] [PMCID]

42. Zhang A, Wang F, Li D, Wang CZ, Yao H, Wan JY, et al. Emerging insights into inflammatory bowel disease from the intestinal microbiota perspective: a bibliometric analysis. Front Immunol. 2023;14:1264705. [DOI:10.3389/fimmu.2023.1264705] [PMID] [PMCID]